Nurix Therapeutics (NRIX) Change in Accured Expenses (2019 - 2025)
Historic Change in Accured Expenses for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $11.0 million.
- Nurix Therapeutics' Change in Accured Expenses rose 2236.26% to $11.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was $17.3 million, marking a year-over-year increase of 4649.63%. This contributed to the annual value of $17.3 million for FY2025, which is 4649.63% up from last year.
- Latest data reveals that Nurix Therapeutics reported Change in Accured Expenses of $11.0 million as of Q4 2025, which was up 2236.26% from $6.3 million recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Change in Accured Expenses ranged from a high of $11.0 million in Q4 2025 and a low of -$7.0 million during Q2 2025
- Moreover, its 5-year median value for Change in Accured Expenses was $3.3 million (2021), whereas its average is $2.3 million.
- As far as peak fluctuations go, Nurix Therapeutics' Change in Accured Expenses skyrocketed by 31468.02% in 2022, and later tumbled by 40287.87% in 2024.
- Over the past 5 years, Nurix Therapeutics' Change in Accured Expenses (Quarter) stood at $3.4 million in 2021, then dropped by 2.51% to $3.3 million in 2022, then dropped by 6.71% to $3.1 million in 2023, then skyrocketed by 193.46% to $9.0 million in 2024, then increased by 22.36% to $11.0 million in 2025.
- Its Change in Accured Expenses was $11.0 million in Q4 2025, compared to $6.3 million in Q3 2025 and -$7.0 million in Q2 2025.